Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. This is a retrospective, real-world mu...

Full description

Bibliographic Details
Authors: Valero-Martínez, C., Urgelles, J.F., Sallés, M., Joven-Ibáñez, B.E., de Juanes, A., Ramírez, J., Juanola, X., Almodóvar, R., Laiz, A., Moreno, M., Pujol, M., Beltrán, E., Pinto Tasende, José Antonio, Crespí, L., Sala-Icardo, L., Castañeda, S., García-Vicuña, R.
Format: article
Publication Date:2023
Country:España
Institution:Servizo Galego de Saúde (SERGAS)
Repository:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/21373
Online Access:https://portalcientifico.sergas.gal//documentos/6574e359c27a3a3585595792
http://hdl.handle.net/20.500.11940/21373
Access Level:Open access
Keyword:Humans
Arthritis, Psoriatic
Tumor Necrosis Factor Inhibitors
Retrospective Studies
Spain
Spondylarthritis
AS A Coruña
INIBIC
id ES_e474494e5c7463bee69dcda330aaa667
oai_identifier_str oai:runa.sergas.gal:20.500.11940/21373
network_acronym_str ES
network_name_str España
repository_id_str
spelling Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from SpainValero-Martínez, C.Urgelles, J.F.Sallés, M.Joven-Ibáñez, B.E.de Juanes, A.Ramírez, J.Juanola, X.Almodóvar, R.Laiz, A.Moreno, M.Pujol, M.Beltrán, E.Pinto Tasende, José AntonioCrespí, L.Sala-Icardo, L.Castañeda, S.García-Vicuña, R.HumansArthritis, PsoriaticTumor Necrosis Factor InhibitorsRetrospective StudiesSpainSpondylarthritisAS A CoruñaINIBICDual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. This is a retrospective, real-world multicenter study in refractory SpA and PsA patients with simultaneous use of two biological or synthetic targeted agents. Effectiveness was assessed using Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Disease Activity in Psoriatic Arthritis (DAPSA) Score. We identified 39 different DTT combinations in 36 patients (22 SpA; 14 PsA), 25 of them with concomitant inflammatory bowel disease. The most commonly used combinations were TNF inhibitor plus antagonist of the IL12/23 pathway, followed by TNF inhibitor plus IL-17 antagonist. During a median exposure of 14.86 months (IQR 8-20.2), DTT retention rate was 69.4% (n=25/36; 19 SpA, 6 PsA). Major clinical improvement (change in ASDAS-CRP > 2 or improvement > 85% in DAPSA) was achieved in 69.4% of patients (n=25/36 therapeutical combinations; 17/21 SpA, 8/15 PsA), with a 58.3% (n=21/36 combinations; 15/20 SpA, 6/13 PsA) low-activity/remission rate. Of the patients who were receiving glucocorticoids, 55% managed to withdraw them during follow-up. Interestingly, only four serious adverse events in three patients were observed, leading to DTT discontinuation.The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.2023info:eu-repo/semantics/articlehttps://portalcientifico.sergas.gal//documentos/6574e359c27a3a3585595792http://hdl.handle.net/20.500.11940/21373reponame:RUNA. Repositorio da Consellería de Sanidade e Sergasinstname:Servizo Galego de Saúde (SERGAS)Ingléshttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:runa.sergas.gal:20.500.11940/213732026-06-12T08:40:47Z
dc.title.none.fl_str_mv Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
title Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
spellingShingle Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
Valero-Martínez, C.
Humans
Arthritis, Psoriatic
Tumor Necrosis Factor Inhibitors
Retrospective Studies
Spain
Spondylarthritis
AS A Coruña
INIBIC
title_short Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
title_full Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
title_fullStr Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
title_full_unstemmed Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
title_sort Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
dc.creator.none.fl_str_mv Valero-Martínez, C.
Urgelles, J.F.
Sallés, M.
Joven-Ibáñez, B.E.
de Juanes, A.
Ramírez, J.
Juanola, X.
Almodóvar, R.
Laiz, A.
Moreno, M.
Pujol, M.
Beltrán, E.
Pinto Tasende, José Antonio
Crespí, L.
Sala-Icardo, L.
Castañeda, S.
García-Vicuña, R.
author Valero-Martínez, C.
author_facet Valero-Martínez, C.
Urgelles, J.F.
Sallés, M.
Joven-Ibáñez, B.E.
de Juanes, A.
Ramírez, J.
Juanola, X.
Almodóvar, R.
Laiz, A.
Moreno, M.
Pujol, M.
Beltrán, E.
Pinto Tasende, José Antonio
Crespí, L.
Sala-Icardo, L.
Castañeda, S.
García-Vicuña, R.
author_role author
author2 Urgelles, J.F.
Sallés, M.
Joven-Ibáñez, B.E.
de Juanes, A.
Ramírez, J.
Juanola, X.
Almodóvar, R.
Laiz, A.
Moreno, M.
Pujol, M.
Beltrán, E.
Pinto Tasende, José Antonio
Crespí, L.
Sala-Icardo, L.
Castañeda, S.
García-Vicuña, R.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Humans
Arthritis, Psoriatic
Tumor Necrosis Factor Inhibitors
Retrospective Studies
Spain
Spondylarthritis
AS A Coruña
INIBIC
topic Humans
Arthritis, Psoriatic
Tumor Necrosis Factor Inhibitors
Retrospective Studies
Spain
Spondylarthritis
AS A Coruña
INIBIC
description Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. This is a retrospective, real-world multicenter study in refractory SpA and PsA patients with simultaneous use of two biological or synthetic targeted agents. Effectiveness was assessed using Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Disease Activity in Psoriatic Arthritis (DAPSA) Score. We identified 39 different DTT combinations in 36 patients (22 SpA; 14 PsA), 25 of them with concomitant inflammatory bowel disease. The most commonly used combinations were TNF inhibitor plus antagonist of the IL12/23 pathway, followed by TNF inhibitor plus IL-17 antagonist. During a median exposure of 14.86 months (IQR 8-20.2), DTT retention rate was 69.4% (n=25/36; 19 SpA, 6 PsA). Major clinical improvement (change in ASDAS-CRP > 2 or improvement > 85% in DAPSA) was achieved in 69.4% of patients (n=25/36 therapeutical combinations; 17/21 SpA, 8/15 PsA), with a 58.3% (n=21/36 combinations; 15/20 SpA, 6/13 PsA) low-activity/remission rate. Of the patients who were receiving glucocorticoids, 55% managed to withdraw them during follow-up. Interestingly, only four serious adverse events in three patients were observed, leading to DTT discontinuation.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://portalcientifico.sergas.gal//documentos/6574e359c27a3a3585595792
http://hdl.handle.net/20.500.11940/21373
url https://portalcientifico.sergas.gal//documentos/6574e359c27a3a3585595792
http://hdl.handle.net/20.500.11940/21373
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:RUNA. Repositorio da Consellería de Sanidade e Sergas
instname:Servizo Galego de Saúde (SERGAS)
instname_str Servizo Galego de Saúde (SERGAS)
reponame_str RUNA. Repositorio da Consellería de Sanidade e Sergas
collection RUNA. Repositorio da Consellería de Sanidade e Sergas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422592439353344
score 15.812429

Similar Items